Drug Trial Radar · NCT04110288
VQI DELTA Paclitaxel Device Safety Analysis
Last checked: Nov 19, 2026Latest source record: Oct 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
219,483
Actual
Start
Jan 1, 2017
Primary completion
Aug 30, 2019
Study completion Apr 1, 2020
Sponsor
- Lead sponsor
- Lahey ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Society for Vascular Surgery Patient Safety Organization
- First posted
- Oct 1, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The VQI-DELTA Paclitaxel Device Safety Analysis seeks to assess the comparative safety of paclitaxel coated balloons and stents in the treatment of peripheral artery disease (PAD) through analysis of the VQI Peripheral Vascular Intervention (PVI) registry module using the DELTA system.
Conditions
- Peripheral Vascular Disease
Interventions
PaclitaxelDrug
Paclitaxel to treat peripheral arterial disease
Non-drug coated Device TreatmentDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival from DeathTime frame: 2 years post intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lahey Clinic, Inc.
Burlington, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.